China Pharmaceutical increases investment in medical device holding subsidiary and increases market development

Sinopharm announced late Thursday that it plans to increase its capital by 24 million yuan to its holding subsidiary Beijing Meikang Baitai Pharmaceutical Technology Co., Ltd., in order to increase market development Industry insiders said that under the background of medical device craze, the addition of Chinese medicine in medical device subsidiaries has made the market have a new understanding of the diversified development of Chinese medicine Meikang Baitai mainly acts as the agent of Beckman company's medical instrument and reagent products in domestic sales, mainly in the form of direct sales to Beijing, Henan, Hebei and other regions The company said that this capital increase can accelerate the transformation and upgrading of Baitai company, strengthen the effective coordination of resources, increase market development efforts, in-depth study of clinical testing and biomedical products, cultivate the main sales products, and enhance the sustainable development ability of Baitai company It is understood that China Pharmaceutical holds 60% of the shares of Meikang Baitai, which will remain unchanged after the capital increase After the capital increase, Meikang Baitai also increased 6.4 million yuan and 5.4 million yuan respectively to its holding subsidiaries Henan Baitai and Hebei Bolin After the capital increase, the shareholding ratio of each shareholder remained unchanged According to the public information, in 2011 and 2012, the sales revenue of Meikang Baitai was 376 million yuan and 560 million yuan respectively.